9-Benzyl-xanthin | 42484-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-Benzyl-xanthin
• 英文别名: 9-Benzyl-1H-purine-2,6(3H,9H)-dione；9-benzyl-3H-purine-2,6-dione
• CAS: 42484-37-7
• 化学式: C₁₂H₁₀N₄O₂
• 分子量: 242.237
• InChiKey: RVEMGEIXXMZTSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-Benzyl-xanthin 以90%的产率得到
  参考文献：
  名称：

  LISTER J. H., AUSTRAL. J. CHEM., 1979, 32, NO 2, 387-397

  摘要：

  DOI：
• 作为产物：
  描述：

  9-Benzylxanthin-8-thion 生成 9-Benzyl-xanthin
  参考文献：
  名称：

  LISTER J. H., AUSTRAL. J. CHEM., 1979, 32, NO 2, 387-397

  摘要：

  DOI：

文献信息

• Substituted O6-benzyl-8-aza-guanines
  申请人：The Government of the United States of America, Department of Health and Human Services

  公开号：US20020013299A1

  公开（公告）日：2002-01-31

  The present invention provides AGT inactivating compounds such as substituted O 6 -benzylguanines of the formula 1 7- or 9-substituted 8-aza-O 6 -benzylguanines, 7,8-disubstituted O 6 -benzylguanines, 7,9-disubstituted O 6 -benzylguanines, 4(6)-substituted 2-amino-5-nitro-6 (4) -benzyloxypyrimidines, and 4 (6) -substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidines, as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent, which causes cytotoxic lesions at the O 6 -position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O 6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the Deposition of guanine.

  本发明提供了AGT失活化合物，例如公式17-或9-取代的8-aza-O6-苄基鸟嘌呤、7,8-二取代的O6-苄基鸟嘌呤、7,9-二取代的O6-苄基鸟嘌呤、4（6）-取代的2-氨基-5-硝基-6（4）-苄氧嘧啶和4（6）-取代的2-氨基-5-亚硝基-6（4）-苄氧嘧啶，以及包含这些化合物和药用载体的制药组合物。本发明还提供了一种增强抗肿瘤烷化剂治疗哺乳动物肿瘤细胞的方法，该方法通过向哺乳动物投与上述化合物、2,4-二氨基-6-苄氧基-s-三嗪、5-取代的2,4-二氨基-6-苄氧基嘧啶或8-aza-O6-苄基鸟嘌呤的有效量，并向哺乳动物投与一种在鸟嘌呤O6位引起细胞毒性损伤的抗肿瘤烷化剂的有效量。
• Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services

  公开号：EP1142893A1

  公开（公告）日：2001-10-10

  The present invention provides AGT inactivating compounds such as substituted O6-benzylguanines, 7- or 9-substituted 8-aza-O6-benzylguanines, 7,8-disubstituted O6-benzylguanines, 7,9-disubstituted O6-benzylguanines, 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidines, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidines, as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesion at the O6-position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O6-benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions of the O6-postion of guanine.

  本发明提供 AGT 失活化合物，如取代的 O6-苄基鸟嘌呤、7-或 9-取代的 8-氮杂-O6-苄基鸟嘌呤、7,8-二取代的 O6-苄基鸟嘌呤、7,9-二取代的 O6-苄基鸟嘌呤、4(6)-取代的 2-氨基-5-亚硝基-6(4)-苄氧基嘧啶，和 4(6)-取代的 2-氨基-5-亚硝基-6(4)-苄氧基嘧啶，以及包含这些化合物和药学上可接受的载体的药物组合物。本发明进一步提供了一种方法，通过向哺乳动物施用有效量的上述化合物之一，用能在鸟嘌呤的 O6 位引起细胞毒性病变的抗肿瘤烷化剂加强对哺乳动物体内肿瘤细胞的化疗、2,4-二氨基-6-苄氧基-s-三嗪、5-取代的 2,4-二氨基-6-苄氧基嘧啶或 8-氮杂-O6-苄基鸟嘌呤，并向哺乳动物施用有效量的抗肿瘤烷化剂，使鸟嘌呤的 O6 位发生细胞毒性病变。
• Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services

  公开号：EP1518854A1

  公开（公告）日：2005-03-30

  The present invention provides AGT inactivating compounds such as 7- or 9-substituted 8- aza- O6-benzylguanines of formula (III) or (IV), and related substituted O6-benzyl guanines, as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumour cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O6- position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, 2,4-diamino-6-benzyloxy-s-triazine, or 8-aza-O6-benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O6- position of guanine.

  本发明提供了AGT失活化合物，如式(III)或(IV)的7-或9-取代的8-氮杂O6-苄基鸟嘌呤和相关的取代的O6-苄基鸟嘌呤，以及包含此类化合物和药学上可接受的载体的药物组合物。本发明进一步提供了一种用抗肿瘤烷化剂加强对哺乳动物体内肿瘤细胞的化疗治疗的方法，该抗肿瘤烷化剂可在鸟嘌呤的 O6-位上引起细胞毒性病变、向哺乳动物施用有效量的上述化合物之一、2,4-二氨基-6-苄氧基-s-三嗪或 8-氮杂-O6-苄基鸟嘌呤，并向哺乳动物施用有效量的抗肿瘤烷化剂，这种抗肿瘤烷化剂可在鸟嘌呤的 O6-位上引起细胞毒性病变。
• JAK INHIBITOR
  申请人：Wuxi Fortune Pharmaceutical Co., Ltd

  公开号：EP3248980A1

  公开（公告）日：2017-11-29

  The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

  本发明公开了一系列 JAK 抑制剂，特别是公开了一种式（I）化合物或其药学上可接受的盐及其在制备治疗 JAK 相关疾病的药物中的用途。
• TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：EP3293177A1

  公开（公告）日：2018-03-14

  The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

  本发明涉及一种酪氨酸激酶抑制剂及其药物组合物。本发明的酪氨酸激酶抑制剂具有下式（I）或（II）所示的结构：